Allovir (NASDAQ:KLRS) Cut to “Sell” at Wall Street Zen

Allovir (NASDAQ:KLRS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Monday.

Allovir Stock Up 0.7%

NASDAQ KLRS opened at $3.08 on Monday. Allovir has a twelve month low of $2.64 and a twelve month high of $24.15.

About Allovir

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.